In women with metastatic breast cancer, a new medicine doubles their chances of survival.

Trastuzumab is an example of inventiveness in the history of little incremental triumphs in the fight against cancer. The new study was led by a team from the International Breast Cancer Center (IBCC) in Barcelona. The country of Spain is depicted in this photograph. The medication trastuzumab deruxtecan was investigated in the Destiny Breast-03 clinical study in patients with HER2-positive metastatic breast cancer, a particularly aggressive subtype of malignant tumours that affects 20% of patients. The medicine, dubbed a Trojan horse by the researchers, mixes a targeted drug (trastuzumab) with a chemotherapeutic treatment (deruxtecan). The first precisely hits the malignant cells, where the HER2 protein is produced, which is responsible for the tumor's rapid progression. When compared to another similar combination, trastuzumab with emtansine, which is now the conventional treatment when patients with these cancers stop responding to the first line, the effects of this medicine sh...